- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02045524
A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers
March 5, 2024 updated by: JDP Therapeutics, Inc.
The objective of this study was to investigate the pharmacokinetics (PK) of JDP-205 injection at 10 mg dose administered by intramuscular injection using various injection techniques in healthy male and female volunteers after a single dose administration.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada
- Algorithme Pharma
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Volunteers meeting all of the following criteria were considered for enrollment in the study:
- Male or female volunteer
- Volunteer aged of at least 18 years
- Volunteer with a body mass index (BMI) greater than or equal to 18.50 and below 30.00 kg/m2
- Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.
- Availability for the entire study period
- Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee
- Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
- Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination (including the examination of the anterolateral thigh muscles) and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis)
- Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer
Exclusion Criteria:
Volunteers presenting any of the following were not included in the study:
- Females who are pregnant or are lactating
- Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study (from the screening visit until study completion)
- History of significant hypersensitivity to cetirizine or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
- History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
- Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
- Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases
- Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS < 60 msec, QRS >110 msec and QTc > 440 msec) on the screening ECG or other clinically significant ECG abnormalities
- Known presence of rare hereditary problems of galactose and /or lactose intolerance
- Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- Any clinically significant illness in the previous 28 days before day 1 of this study
- Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
- Use of antihistaminic medication in the previous 7 days before day 1 of this study
- Any history of tuberculosis and/or prophylaxis for tuberculosis
- Positive urine screening of ethanol and/or drugs of abuse
- Positive results to HIV, HBsAg or anti-HCV tests
- Females who are pregnant according to a positive serum pregnancy test
- Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study
- Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Injection location1
Single dose IM injection
|
|
Experimental: Injection location 2
Single dose IM Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in pharmacokinetics: Difference in AUC
Time Frame: 8 hours post dose
|
8 hours post dose
|
Differences in pharmacokinetics: difference in Cmax
Time Frame: 8 hours post dose
|
8 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
January 22, 2014
First Submitted That Met QC Criteria
January 23, 2014
First Posted (Estimated)
January 27, 2014
Study Record Updates
Last Update Posted (Actual)
March 6, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ETTAU-01P (CTN-P1-571)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Urticaria
-
JDP Therapeutics, Inc.Algorithme Pharma IncCompleted
-
JDP Therapeutics, Inc.CompletedAcute UrticariaCanada, United States
-
JDP Therapeutics, Inc.CompletedAcute UrticariaUnited States, Canada
-
University Hospital, ToulouseCompleted
-
Marcus MaurerCompletedNon-autoreactive Chronic Spontaneous Urticaria | Autoimmune Chronic Spontaneous Urticaria | Autoreactive, Non-autoimmune Chronic Spontaneous UrticariaGermany
-
J. Uriach and CompanyTerminated
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedUrticaria ChronicUnited States
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
University Hospital Inselspital, BerneNovartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-ACCompletedChronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous UrticariaSwitzerland
-
United BioPharmaCompleted
Clinical Trials on Deep muscle injection
-
Ataturk UniversityCompletedCOPD | Progressive Muscle Relaxation | Deep BreathTurkey
-
Riphah International UniversityCompletedCesarean Section ComplicationsPakistan
-
Youngstown State UniversityRecruiting
-
Riphah International UniversityCompletedInspiratory Muscle TrainingPakistan
-
Riphah International UniversityCompletedPost-Hysterectomy Vaginal Vault ProlapsePakistan
-
Hacettepe UniversityCompletedMusculoskeletal Disorder of the Neck
-
Wake Forest UniversityActive, not recruiting
-
Riphah International UniversityCompletedAdhesive CapsulitisPakistan
-
Riphah International UniversityCompleted
-
Palo Alto Veterans Institute for ResearchVA Palo Alto Health Care System; Brain & Behavior Research FoundationCompletedAnxiety DisordersUnited States